SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-23-000611
Filing Date
2023-12-08
Accepted
2023-12-08 14:11:53
Documents
1
Group Members
ANTHONY A. FLORENCE, JR.FOREST BASKETTMOHAMAD H. MAKHZOUMINEA 15 GP, LLCNEA PARTNERS 15, L.P.NEW ENTERPRISE ASSOCIATES 15, L.P.SCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#5) geoiv-addex_18778.htm SC 13D/A 309445
  Complete submission text file 0001072613-23-000611.txt   311315
Mailing Address CHEMIN DES MINES 9 GENEVA V8 CH-1202
Business Address CHEMIN DES MINES 9 GENEVA V8 CH-1202 01141228841555
Addex Therapeutics Ltd. (Subject) CIK: 0001574232 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91805 | Film No.: 231474978
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities Fund IV, LLC (Filed by) CIK: 0001644965 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A